Evidence map›Paper›PMID 35505393›Full record

ArticleGenome medicine2022

Introduction and transmission of SARS-CoV-2 lineage B.1.1.7, Alpha variant, in Denmark.

Thomas Y Michaelsen, Marc Bennedbæk, Lasse E Christiansen, Mia S F Jørgensen, Camilla H Møller, Emil A Sørensen, Simon Knutsson, Jakob Brandt, Thomas B N Jensen, Clarisse Chiche-Lapierre and 18 more

Abstract read
In one paragraph

Article in Genome medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Tracing SARS-CoV-2 clusters across local scales using genomic data.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Thomas Y MichaelsenDepartment of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.
Marc BennedbækCentre of Excellence for Health, Immunity and Infection (CHIP), Department of Infectious Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Lasse E ChristiansenDepartment of Applied Mathematics and Computer Science, Technical University of Denmark, Lyngby, Denmark.
Mia S F JørgensenInfectious Disease Epidemiology & Prevention, Statens Serum Institut, Copenhagen, Denmark.
Camilla H MøllerInfectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark.
Emil A SørensenDepartment of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.
Simon KnutssonDepartment of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.
Jakob BrandtDepartment of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.
Thomas B N JensenDepartment of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.
Clarisse Chiche-LapierreDepartment of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.
Emilio F ColladosDepartment of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.
Trine SørensenDepartment of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.
Celine PetersenDepartment of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.
Vang Le-QuyUnit for Research Data Services (CLAAUDIA), Aalborg University, Aalborg, Denmark.
Mantas SereikaDepartment of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.
Frederik T HansenDepartment of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark.
Morten RasmussenDepartment of Virus & Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark.
Jannik FonagerDepartment of Virus & Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark.
Søren M KarstDepartment of Virus & Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark.
Rasmus L MarvigCenter for Genomic Medicine, Rigshospitalet, Copenhagen, Denmark.
Marc SteggerDepartment of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.
Raphael N SieberDepartment of Bacteria, Parasites and Fungi, Statens Serum Institut, Copenhagen, Denmark.
Robert SkovInfectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark.
Rebecca LegarthInfectious Disease Epidemiology & Prevention, Statens Serum Institut, Copenhagen, Denmark.
Tyra G KrauseInfectious Disease Preparedness, Statens Serum Institut, Copenhagen, Denmark.
Anders FomsgaardDepartment of Virus & Microbiological Special Diagnostics, Statens Serum Institut, Copenhagen, Denmark.
Danish COVID-19 Genome Consortium (DCGC)
Mads AlbertsenDepartment of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark. ma@bio.aau.dk.ORCID 0000-0002-6151-190X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn early 2021, the SARS-CoV-2 lineage B.1.1.7 (Alpha variant) became dominant across large parts of the world. In Denmark, comprehensive and real-time test, contact-tracing, and sequencing efforts were applied to sustain epidemic control. Here, we use these data to investigate the transmissibility, introduction, and onward transmission of B.1.1.7 in Denmark.

methodsWe analyzed a comprehensive set of 60,178 SARS-CoV-2 genomes generated from high-throughput sequencing by the Danish COVID-19 Genome Consortium, representing 34% of all positive cases in the period 14 November 2020 to 7 February 2021. We calculated the transmissibility of B.1.1.7 relative to other lineages using Poisson regression. Including all 1976 high-quality B.1.1.7 genomes collected in the study period, we constructed a time-scaled phylogeny, which was coupled with detailed travel history and register data to outline the introduction and onward transmission of B.1.1.7 in Denmark.

resultsIn a period with unchanged restrictions, we estimated an increased B.1.1.7 transmissibility of 58% (95% CI: [56%, 60%]) relative to other lineages. Epidemiological and phylogenetic analyses revealed that 37% of B.1.1.7 cases were related to the initial introduction in November 2020. The relative number of cases directly linked to introductions varied between 10 and 50% throughout the study period.

conclusionsOur findings corroborate early estimates of increased transmissibility of B.1.1.7. Both substantial early expansion when B.1.1.7 was still unmonitored and continuous foreign introductions contributed considerably to case numbers. Finally, our study highlights the benefit of balanced travel restrictions and self-isolation procedures coupled with comprehensive surveillance efforts, to sustain epidemic control in the face of emerging variants.

Indexed as

COVID-19SARS-CoV-2DenmarkHumansPhylogeny

Identifiers

PMID35505393
PMCPMC9064402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.